Synergistic neuroprotective effects of combined treatment with olmesartan plus azelnidipine in stroke-prone spontaneously hypertensive rats

Journal of Neuroscience Research

Volumn 92, Issue 10, 2014, Pages 1330-1337

  Omote, Yoshio ^a   Deguchi, Kentaro ^a   Kono, Syoichiro ^a   Liu, Wentao ^a   Kurata, Tomoko ^a   Hishikawa, Nozomi ^a   Yamashita, Toru ^a   Ikeda, Yoshio ^a   Abe, Koji ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Azelnidipine; Neurovascular unit; Olmesartan; Oxidative stress; SHR SP

Indexed keywords

AZELNIDIPINE; OLMESARTAN; AZETIDINE 2 CARBOXYLIC ACID; CCL2 PROTEIN, RAT; COLLAGEN TYPE 4; DIHYDROPYRIDINE DERIVATIVE; GELATINASE B; IMIDAZOLE DERIVATIVE; MONOCYTE CHEMOTACTIC PROTEIN 1; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BRAIN BLOOD FLOW; BRAIN INFARCTION SIZE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIGITAL MICROSCOPE; DOSE RESPONSE; DRUG EFFICACY; INFLAMMATION; LOW DRUG DOSE; MALE; MONOTHERAPY; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; STROKE PRONE SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; AGE; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD PRESSURE; BRAIN INJURIES; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; DRUG POTENTIATION; GENE EXPRESSION REGULATION; GENETICS; HEART RATE; LASER DOPPLER FLOWMETRY; METABOLISM; MOTOR ACTIVITY; PATHOLOGY; SPONTANEOUSLY HYPERTENSIVE RAT; STROKE;

AGE FACTORS; ANIMALS; AZETIDINECARBOXYLIC ACID; BLOOD PRESSURE; BRAIN INJURIES; CHEMOKINE CCL2; COLLAGEN TYPE IV; DIHYDROPYRIDINES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; GENE EXPRESSION REGULATION; HEART RATE; IMIDAZOLES; LASER-DOPPLER FLOWMETRY; MALE; MATRIX METALLOPROTEINASE 9; MOTOR ACTIVITY; OXIDATIVE STRESS; RATS; RATS, INBRED SHR; STROKE; TETRAZOLES;

EID: 84905910492     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.23406     Document Type: Article

References (19)

1. Augustin HG, Braun K, Telemenakis I, Modlich U, Kuhn W. 1995. Ovarian angiogenesis. Phenotypic characterization of endothelial cells in a physiological model of blood vessel growth and regression. Am J Pathol 147:339-351.
2. Blezer EL, Nicolay K, Bar D, Goldschmeding R, Jansen GH, Koomans HA, Joles JA. 1998. Enalapril prevents imminent and reduces manifest cerebral edema in stroke-prone hypertensive rats. Stroke 29:1671-1677, discussion 1677-1678.
3. Chuang YC, Wu MS, Su YK, Fang KM. 2012. Effects of olmesartan on arterial stiffness in rats with chronic renal failure. Cardiovasc Diabetol 11:66.
4. Daikuhara H, Kikuchi F, Ishida T. 2012. The combination of OLmesartan and a CAlcium channel blocker (azelnidipine) or candesartan and a calcium channel blocker (amlodipine) in type 2 diabetic hypertensive patients: the OLCA study. Diab Vasc Dis Res 9:280-286.
5. Hamakawa Y, Omori N, Ouchida M, Nagase M, Sato K, Nagano I, Shoji M, Fujita T, Abe K. 2004. Severity dependent upregulations of LOX-1 and MCP-1 in early sclerotic changes of common carotid arteries in spontaneously hypertensive rats. Neurol Res 26:767-773.
6. Hosomi N, Nishiyama A, Ban CR, Naya T, Takahashi T, Kohno M, Koziol JA. 2005. Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 134:225-231.
7. Iwai M, Li HS, Chen R, Shiuchi T, Wu L, Min LJ, Li JM, Tsuda M, Suzuki J, Tomono Y, Tomochika H, Mogi M, Horiuchi M. 2006. Calcium channel blocker azelnidipine reduces glucose intolerance in diabetic mice via different mechanism than angiotensin receptor blocker olmesartan. J Pharmacol Exp Ther 319:1081-1087.
8. Kawai H, Deguchi S, Deguchi K, Yamashita T, Ohta Y, Shang J, Tian F, Zhang X, Liu N, Liu W, Ikeda Y, Matsuura T, Abe K. 2011. Synergistic benefit of combined amlodipine plus atorvastatin on neuronal damage after stroke in Zucker metabolic rat. Brain Res 1368:317-323.
9. Kurobe H, Matsuoka Y, Hirata Y, Sugasawa N, Maxfield MW, Sata M, Kitagawa T. 2013. Azelnidipine suppresses the progression of aortic aneurysm in wild mice model through anti-inflammatory effects. J Thorac Cardiovasc Surg 146:1501-1508.
10. Lukic-Panin V, Kamiya T, Zhang H, Hayashi T, Tsuchiya A, Sehara Y, Deguchi K, Yamashita T, Abe K. 2007. Prevention of neuronal damage by calcium channel blockers with antioxidative effects after transient focal ischemia in rats. Brain Res 1176:143-150.
11. Namikoshi T, Tomita N, Satoh M, Haruna Y, Kobayashi S, Komai N, Sasaki T, Kashihara N. 2007. Olmesartan ameliorates renovascular injury and oxidative stress in Zucker obese rats enhanced by dietary protein. Am J Hypertens 20:1085-1091.
12. Noda K, Hosoya M, Nakajima S, Ohashi J, Fukumoto Y, Shimokawa H. 2012. Antiatherogenic effects of the combination therapy with olmesartan and azelnidipine in diabetic apolipoprotein E-deficient mice. Tohoku J Exp Med 228:305-315.
13. Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K. 2012. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients. Am J Med 125:981-990.
14. Ohta Y, Kamiya T, Nagai M, Nagata T, Morimoto N, Miyazaki K, Murakami T, Kurata T, Takehisa Y, Ikeda Y, Asoh S, Ohta S, Abe K. 2008. Therapeutic benefits of intrathecal protein therapy in a mouse model of amyotrophic lateral sclerosis. J Neurosci Res 86:3028-3037.
15. Pelisch N, Hosomi N, Ueno M, Nakano D, Hitomi H, Mogi M, Shimada K, Kobori H, Horiuchi M, Sakamoto H, Matsumoto M, Kohno M, Nishiyama A. 2011. Blockade of AT1 receptors protects the blood-brain barrier and improves cognition in Dahl salt-sensitive hypertensive rats. Am J Hypertens 24:362-368.
16. Rafiq K, Sherajee SJ, Hitomi H, Nakano D, Kobori H, Ohmori K, Mori H, Kobara H, Masaki T, Kohno M, Nishiyama A. 2013. Calcium channel blocker enhances beneficial effects of an angiotensin II AT1 receptor blocker against cerebrovascular-renal injury in type 2 diabetic mice. PLoS One 8:e82082.
17. Rastas S, Pirttila T, Mattila K, Verkkoniemi A, Juva K, Niinisto L, Lansimies E, Sulkava R. 2010. Vascular risk factors and dementia in the general population aged >85 years: prospective population-based study. Neurobiol Aging 31:1-7.
18. Shinohara K, Hirooka Y, Ogawa K, Kishi T, Yasukawa K, Utsumi H, Sunagawa K. 2012. Combination therapy of olmesartan and azelnidipine inhibits sympathetic activity associated with reducing oxidative stress in the brain of hypertensive rats. Clin Exp Hypertens 34:456-462.
19. Takahashi T, Konta T, Takasaki S, Ichikawa K, Takeishi Y, Kubota I. 2007. An angiotensin II type-I receptor blocker, olmesartan medoxomil, attenuates lipid peroxidation in renal injury induced by subtotal nephrectomy. Clin Exp Nephrol 11:202-208.